Latest Insider Transactions at Laboratory Corp Of America Holdings (LH)
This section provides a real-time view of insider transactions for Laboratory Corp Of America Holdings (LH). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of LABORATORY CORP OF AMERICA HOLDINGS to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of LABORATORY CORP OF AMERICA HOLDINGS's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 04
2021
|
Jean Luc Belingard Director |
SELL
Payment of exercise price or tax liability
|
Direct |
99
-0.63%
|
$22,077
$223.78 P/Share
|
|
Feb 04
2021
|
Jean Luc Belingard Director |
BUY
Exercise of conversion of derivative security
|
Direct |
986
+5.92%
|
-
|
|
Feb 04
2021
|
Judith C Seltz EVP, CHRO |
SELL
Payment of exercise price or tax liability
|
Direct |
96
-9.51%
|
$21,408
$223.78 P/Share
|
|
Feb 04
2021
|
Judith C Seltz EVP, CHRO |
BUY
Exercise of conversion of derivative security
|
Direct |
280
+21.71%
|
-
|
|
Feb 04
2021
|
Lance Berberian EVP, CIO & CTO |
SELL
Payment of exercise price or tax liability
|
Direct |
131
-1.2%
|
$29,213
$223.78 P/Share
|
|
Feb 04
2021
|
Lance Berberian EVP, CIO & CTO |
BUY
Exercise of conversion of derivative security
|
Direct |
373
+3.3%
|
-
|
|
Feb 04
2021
|
Brian J Caveney EVP, Pres of ED, CMO & CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
190
-3.92%
|
$42,370
$223.78 P/Share
|
|
Feb 04
2021
|
Brian J Caveney EVP, Pres of ED, CMO & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
560
+10.37%
|
-
|
|
Feb 04
2021
|
Glenn A Eisenberg Chief Financial Officer, EVP |
SELL
Payment of exercise price or tax liability
|
Direct |
306
-0.95%
|
$68,238
$223.78 P/Share
|
|
Feb 04
2021
|
Glenn A Eisenberg Chief Financial Officer, EVP |
BUY
Exercise of conversion of derivative security
|
Direct |
970
+2.93%
|
-
|
|
Feb 04
2021
|
Paul R Kirchgraber CEO, Covance Drug Development |
SELL
Payment of exercise price or tax liability
|
Direct |
187
-2.26%
|
$41,701
$223.78 P/Share
|
|
Feb 04
2021
|
Paul R Kirchgraber CEO, Covance Drug Development |
BUY
Exercise of conversion of derivative security
|
Direct |
560
+6.35%
|
-
|
|
Feb 04
2021
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
154
-3.42%
|
$34,342
$223.78 P/Share
|
|
Feb 04
2021
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
BUY
Exercise of conversion of derivative security
|
Direct |
560
+11.05%
|
-
|
|
Feb 04
2021
|
Amy B. Summy EVP, Chief Marketing Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
94
-35.34%
|
$20,962
$223.78 P/Share
|
|
Feb 04
2021
|
Amy B. Summy EVP, Chief Marketing Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
266
+50.0%
|
-
|
|
Feb 04
2021
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
83
-1.88%
|
$18,509
$223.78 P/Share
|
|
Feb 04
2021
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
300
+6.37%
|
-
|
|
Feb 04
2021
|
Peter J Wilkinson SVP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
53
-9.2%
|
$11,819
$223.78 P/Share
|
|
Feb 04
2021
|
Peter J Wilkinson SVP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
150
+20.66%
|
-
|
|
Feb 04
2021
|
Adam H Schechter President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,028
-8.35%
|
$229,244
$223.78 P/Share
|
|
Feb 04
2021
|
Adam H Schechter President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,506
+22.16%
|
-
|
|
Jan 26
2021
|
R Sanders Williams Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,300
+19.86%
|
$127,400
$98.49 P/Share
|
|
Dec 03
2020
|
Kerrii B Anderson Director |
SELL
Bona fide gift
|
Direct |
746
-3.8%
|
-
|
|
Dec 01
2020
|
Jeffrey A. Davis Director |
BUY
Exercise of conversion of derivative security
|
Direct |
173
+50.0%
|
-
|
|
Nov 06
2020
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
SELL
Open market or private sale
|
Direct |
588
-12.96%
|
$125,832
$214.59 P/Share
|
|
Nov 05
2020
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
835
-15.54%
|
$178,690
$214.42 P/Share
|
|
Nov 05
2020
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,010
+27.23%
|
-
|
|
Nov 05
2020
|
Brian J Caveney EVP, Pres of ED, CMO & CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
886
-17.35%
|
$189,604
$214.42 P/Share
|
|
Nov 05
2020
|
Brian J Caveney EVP, Pres of ED, CMO & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,010
+28.24%
|
-
|
|
Nov 04
2020
|
Paul R Kirchgraber CEO, Covance Drug Development |
SELL
Open market or private sale
|
Direct |
1,500
-16.31%
|
$321,000
$214.14 P/Share
|
|
Nov 02
2020
|
Paul R Kirchgraber CEO, Covance Drug Development |
SELL
Payment of exercise price or tax liability
|
Direct |
895
-8.87%
|
$185,265
$207.23 P/Share
|
|
Nov 02
2020
|
Paul R Kirchgraber CEO, Covance Drug Development |
BUY
Exercise of conversion of derivative security
|
Direct |
2,006
+17.9%
|
-
|
|
Nov 02
2020
|
Adam H Schechter President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
885
-9.13%
|
$183,195
$207.23 P/Share
|
|
Nov 02
2020
|
Adam H Schechter President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,006
+17.14%
|
-
|
|
Nov 02
2020
|
Glenn A Eisenberg Chief Financial Officer, EVP |
SELL
Payment of exercise price or tax liability
|
Direct |
4,034
-11.48%
|
$835,038
$207.23 P/Share
|
|
Nov 02
2020
|
Glenn A Eisenberg Chief Financial Officer, EVP |
BUY
Exercise of conversion of derivative security
|
Direct |
9,024
+20.43%
|
-
|
|
Sep 21
2020
|
R Sanders Williams Director |
SELL
Bona fide gift
|
Direct |
1,149
-22.55%
|
-
|